Tech Company Financing Transactions

Celator Pharmaceuticals Funding Round

Celator Pharmaceuticals, based in Princeton, raised $20 million from Thomas, McNerny & Partners, BDC Venture Capital and Domain Associates.

Transaction Overview

Company Name
Celator Pharmaceuticals
Announced On
9/1/2010
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series D
Investors

Thomas, McNerny & Partners (Lead Investor) (Alexander Zisson)

BDC Venture Capital

Domain Associates (Nicole Vitullo)

Growthworks Capital

Quaker Partners (Brenda Gavin)

TL Ventures

Ventures West (Kenneth Galbraith)

Proceeds Purpose
The Princeton, N.J.-based cancer treatment developer plans to use proceeds to complete clinical trials and other efforts to advance its CPX-351 liposome injection as a treatment for acute myeloid leukemia.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
200 Princeton South Corporate Centre 180
Princeton, NJ 08628
USA
Phone
609-243-0123
Website
www.celatorpharma.com
Email Address
[email protected]
Overview
Celator biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes in cancer.
Profile
Celator Pharmaceuticals LinkedIn Company Profile
Social Media
Celator Pharmaceuticals Company Twitter Account
Company News
Celator Pharmaceuticals News
Facebook
Celator Pharmaceuticals on Facebook
YouTube
Celator Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Scott Jackson
  Scott Jackson LinkedIn Profile  Scott Jackson Twitter Account  Scott Jackson News  Scott Jackson on Facebook
Chief Financial Officer
Fred Powell
  Fred Powell LinkedIn Profile  Fred Powell Twitter Account  Fred Powell News  Fred Powell on Facebook
Chief Medical Officer
Arthur Louie
  Arthur Louie LinkedIn Profile  Arthur Louie Twitter Account  Arthur Louie News  Arthur Louie on Facebook
President
Lawrence Mayer
  Lawrence Mayer LinkedIn Profile  Lawrence Mayer Twitter Account  Lawrence Mayer News  Lawrence Mayer on Facebook
VP - Regulatory Affairs
Lisa DeLuca
  Lisa DeLuca LinkedIn Profile  Lisa DeLuca Twitter Account  Lisa DeLuca News  Lisa DeLuca on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/1/2010: Accumetrics venture capital transaction
Next: 9/1/2010: Copiun venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to document every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.